Indo US Bio-Tech Ltd.

As of June 30, 2026, Indo US Bio-Tech Ltd. carries a market capitalization of 1.76B, placing it among publicly traded companies globally. Its enterprise value stands at 1.76B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Indo US Bio-Tech Ltd. has 20.05M shares outstanding.

As of June 30, 2026, Indo US Bio-Tech Ltd. trades at a trailing price-to-earnings ratio of 15.37.

As of June 30, 2026, Indo US Bio-Tech Ltd. trades at an EV/EBITDA multiple of 11.33 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.56 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 12.09 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 1.76B versus a market cap of 1.76B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 1.28M in revenue per employee across its workforce of 883.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Indo US Bio-Tech Ltd. recorded 7.20M in income tax expense. That works out to an effective tax rate of 5.91, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 121.77M, leaving 114.58M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Indo US Bio-Tech Ltd.'s stock has declined approximately 48.28% over the past 52 weeks. The 50-day moving average sits at 77.97, while the 200-day moving average is 99.06.

Over the twelve months ended June 30, 2026, Indo US Bio-Tech Ltd. generated 1.13B in revenue and converted that into 114.58M in net income, yielding earnings per share of 5.70. EBITDA reached 155.03M, while operating income came in at 145.32M.

Over the twelve months ended June 30, 2026, Indo US Bio-Tech Ltd. posted a gross margin of 25.28, reflecting its pricing power and cost economics. The operating margin of 12.90 and net profit margin of 10.17 provide insight into operational efficiency.

Indo US Bio-Tech Ltd.'s most recent stock split took place on August 29, 2023 with a 1:2 split ratio.